If you are not happy with the results below please do another search
Epygenix Therapeutics, Inc. is developing precision medicine for rare and catastrophic forms of genetic epilepsy, such as Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, and Otahara syndrome.
How To Find Us
140 E. Ridgewood Ave.
Suite 415, South Tower
Paramus, NJ 07652
Phone: 1 (201) 940-7377
Fax: 1 (201) 940-7218
- Epygenix Therapeutics Receives US FDA Orphan Drug Designation For EPX-300 For The Treatment Of Patients With Dravet Syndrome.
- A New School of Drug Discovery
- Profile of Epygenix Therapeutics is listed in June 2017 issue of Biopharma Dealmakers – Published in Nature Reviews Drug Discovery & Nature Biotechnology
- Epygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome